Join
Live feed
·
PRReleasevia Quantisnow
BridgeBio Pharma Inc. logo

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

ByQuantisnow·Wall Street's wire, on your screen.
BBIO· BridgeBio Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BBIO (BridgeBio Pharma Inc.) and more on Quantisnow.